Form 4: Sarepta Executive Vests Equity, Covers Taxes
Insider Transaction Report
Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, reported the vesting of performance stock units and restricted stock units, followed by tax-related share dispositions.
Summary
- Louise Rodino-Klapac, President, R&D and Tech Ops at Sarepta Therapeutics, Inc. (SRPT), reported transactions related to her equity compensation.
- On March 1, 2026, 8,125 shares of common stock were acquired upon the vesting of a Performance Stock Unit (PSU) award granted on March 1, 2024. The vesting was based on the Compensation Committee's determination of the company's achievement of prescribed milestones.
- Following this, on March 2, 2026, 3,718 shares were disposed of at $16.2 per share to satisfy tax withholding obligations related to the PSU vesting.
- Additionally, on March 2, 2026, 767 shares were disposed of at $16.2 per share to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on March 1, 2024.
- After these transactions, Rodino-Klapac beneficially owns 227,670 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It reports standard executive compensation events (equity vesting and tax-related share dispositions) and does not indicate any significant positive or negative operational or financial developments.
Positives
- The vesting of Performance Stock Units indicates the company achieved prescribed milestones, reflecting positively on company performance.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that routine insider transactions like equity award vestings and subsequent tax-related dispositions are common in the biotechnology and pharmaceutical sectors, reflecting standard executive compensation practices tied to performance and retention. These events typically do not signal a change in company fundamentals or strategic direction.
Related Party Transactions
- The transactions involve the vesting of equity awards granted by Sarepta Therapeutics to its President, R&D and Tech Ops, Louise Rodino-Klapac, and subsequent share dispositions to cover tax obligations, which are standard related-party compensation events.
Stakeholder Impact
- Shareholders: Minimal direct impact as these are routine compensation events. The vesting of PSUs could be seen as a positive signal regarding company performance against internal milestones.
- Employees: No direct impact mentioned.
- Management: Louise Rodino-Klapac's beneficial ownership remains substantial, aligning her interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Grant date of Performance Stock Unit (PSU) award and Restricted Stock Unit (RSU) award to Louise Rodino-Klapac. |
| March 1, 2026 | Vesting date of 8,125 shares from a PSU award for Louise Rodino-Klapac. |
| March 2, 2026 | Date of disposition of shares for tax withholding related to PSU and RSU vesting. |
| March 3, 2026 | Date the Form 4 was signed by attorney-in-fact. |
Keywords
Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, Equity Vesting, Performance Stock Units, Restricted Stock Units, Tax Withholding, Louise Rodino-Klapac, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.